Progressive worsening of adaptive functions in Down syndrome may be mediated by the complexing of soluble Aβ peptides with the α 7 nicotinic acetylcholine receptor: Therapeutic implications

Clinical Neuropharmacology

Volumn 26, Issue 5, 2003, Pages 277-283

  Deutsch, Stephen I ^a,b,c   Rosse, Richard B ^a,b   Mastropaolo, John ^a   Chilton, Melissa ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

7 nicotinic acetylcholine receptor; A peptides; Down syndrome

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE;

ADAPTATION; AGING; ALZHEIMER DISEASE; ARTICLE; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; COMPLEX FORMATION; CYTOTOXICITY; DAILY LIFE ACTIVITY; DISEASE EXACERBATION; DOWN SYNDROME; ELECTROPHYSIOLOGY; GENE DOSAGE; PRIORITY JOURNAL; PROTEIN PROCESSING; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TRISOMY 21;

ACTIVITIES OF DAILY LIVING; ADAPTATION, PHYSIOLOGICAL; AMYLOID BETA-PROTEIN; ANIMALS; CHOLINESTERASE INHIBITORS; DOWN SYNDROME; HUMANS; PEPTIDE FRAGMENTS; RECEPTORS, NICOTINIC;

EID: 0141532939     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200309000-00013     Document Type: Article

References (28)

1. Lindstrom J. Nicotinic acetylcholine receptors in health and disease. Mol Neurobiol. 1997;15:193-222.
2. Lena C, Changeux J-P. Allosteric nicotinic receptors, human pathologies. J Physiol (Paris). 1998;92:63-74.
3. Weiland S, Bertrand D, Leonard S. Neuronal nicotinic receptors: from the gene to the disease. Behav Brain Res. 2000;113:43-56.
4. Albuquerque EX, Alkondon M, Pereira EFR, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther. 1997;280:1117-1136.
5. 7 nicotinic acetylcholine receptor in neuronal plasticity. Mol Neurobiol. 1999;20:1-16.
6. Gerzanich V, Anand R, Lindstrom J. Homomers of α8 subunits of nicotinic receptors functionally expressed in Xenopus oocytes exhibit similar channel but contrasting binding site properties compared to α7 homomers. Mol Pharmacol. 1994;45:212-220.
7. 7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci. 1997;9:2734-2742.
8. 7 nicotinic receptors in rat hippocampal neurons. Brain Res. 2000;882:155-168.
9. 7 receptors. J Physiol (Paris). 1998;92:309-316.
10. Adler LE, Olincy A, Waldo M, et al. Schizophrenia, sensory gating, and nicotine receptors. Schizophr Bull. 1998;24:189-202.
11. Freedman R, Hall M, Adler LE, et al. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995;38:22-33.
12. Court J, Spurden D, Lloyd S, et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: α-bungarotoxin and nicotine binding in the thalamus. J Neurochem. 1999;73:1590-1597.
13. 7 subunit in the frontal cortex from schizophrenic brain. Neuroreport. 1999;10:1779-1782.
14. Marutle A, Zhang X, Court J, et al. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat. 2001;22:115-126.
15. 1-42 binds to α7 nicotinic acetylcholine receptor with high affinity. J Biol Chem. 2000;275:5626-5632.
16. Liu Q-S, Kawai H, Berg DK. β-Amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A. 2001;98:4734-4739.
17. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985;17:278-282.
18. Gyure KA, Durham R, Stewart WF, et al. Intraneuronal Aβ-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med. 2001;125:489-492.
19. Teller JK, Russo C, DeBusk LM, et al. Presence of soluble amyloid β-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med. 1996;2:93-95.
20. Mori C, Spooner ET, Wisniewski KE, et al. Intraneuronal Aβ42 accumulation in Down syndrome brain. Amyloid. 2002;9:88-102.
21. 42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem. 1996;271:8966-8970.
22. Kishnani PS, Sullivan JA, Walter BK, et al. Cholinergic therapy for Down's syndrome. Lancet. 1999;353:1064-1065.
23. Hemingway-Eltomey JM, Lemer AJ. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome (letter). Am J Psychiatry. 1999;156:1470.
24. Lott IT, Osann K, Doran E, et al. Down syndrome and Alzheimer disease. Response to donepezil. Arch Neurol. 2002;59:1133-1136.
25. Kishnani PS, Spiridigliozzi GA, Heller JH, et al. Donepezil for Down's syndrome (letter). Am J Psychiatry. 2001;158:143.
26. Raskind MA, Peskind ER, Wessel T, et al. Galanthamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-2268.
27. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galanthamine in AD. Neurology. 2000; 54:2269-2276.
28. Rosse RB, Deutsch SI. Adjuvant galanthamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol. 2002;25:272-275.